Perez M - Search Results

1

DNA methylation signatures identify biologically distinct thyroid cancer subtypes.

Rodríguez-Rodero S, Fernández AF, Fernández-Morera JL, Castro-Santos P, Bayon GF, Ferrero C, Urdinguio RG, Gonzalez-Marquez R, Suarez C, Fernández-Vega I, Fresno Forcelledo MF, Martínez-Camblor P, Mancikova V, Castelblanco E, Perez M, Marrón PI, Mendiola M, Hardisson D, Santisteban P, Riesco-Eizaguirre G, Matías-Guiu X, Carnero A, Robledo M, Delgado-Álvarez E, Menéndez-Torre E, Fraga MF. Rodríguez-Rodero S, et al. Among authors: perez m. J Clin Endocrinol Metab. 2013 Jul;98(7):2811-21. doi: 10.1210/jc.2012-3566. Epub 2013 May 10. J Clin Endocrinol Metab. 2013. PMID: 23666970

2

MAP17 and SGLT1 protein expression levels as prognostic markers for cervical tumor patient survival.

Perez M, Praena-Fernandez JM, Felipe-Abrio B, Lopez-Garcia MA, Lucena-Cacace A, Garcia A, Lleonart M, Roncador G, Marin JJ, Carnero A. Perez M, et al. PLoS One. 2013;8(2):e56169. doi: 10.1371/journal.pone.0056169. Epub 2013 Feb 13. PLoS One. 2013. PMID: 23418532 Free PMC article.

3

MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NFκB Activation in Breast Cancer.

Muñoz-Galván S, Gutierrez G, Perez M, Carnero A. Muñoz-Galván S, et al. Among authors: perez m. Mol Cancer Ther. 2015 Jun;14(6):1454-65. doi: 10.1158/1535-7163.MCT-14-1053. Epub 2015 Apr 2. Mol Cancer Ther. 2015. PMID: 25837675

4

Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA.

Perez M, Muñoz-Galván S, Jiménez-García MP, Marín JJ, Carnero A. Perez M, et al. Oncotarget. 2015 Dec 1;6(38):40557-74. doi: 10.18632/oncotarget.5829. Oncotarget. 2015. PMID: 26528855 Free PMC article.

5

Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src.

Perez M, Lucena-Cacace A, Marín-Gómez LM, Padillo-Ruiz J, Robles-Frias MJ, Saez C, Garcia-Carbonero R, Carnero A. Perez M, et al. Oncotarget. 2016 May 31;7(22):33111-24. doi: 10.18632/oncotarget.8880. Oncotarget. 2016. PMID: 27105527 Free PMC article.

6

Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1).

Perez M, Peinado-Serrano J, Garcia-Heredia JM, Felipe-Abrio I, Tous C, Ferrer I, Martin-Broto J, Saez C, Carnero A. Perez M, et al. Oncotarget. 2016 Oct 11;7(41):67033-67046. doi: 10.18632/oncotarget.11475. Oncotarget. 2016. PMID: 27563810 Free PMC article.

7

The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB.

Garcia-Heredia JM, Lucena-Cacace A, Verdugo-Sivianes EM, Pérez M, Carnero A. Garcia-Heredia JM, et al. Among authors: perez m. Clin Cancer Res. 2017 Jul 15;23(14):3871-3883. doi: 10.1158/1078-0432.CCR-16-2358. Epub 2017 Feb 2. Clin Cancer Res. 2017. PMID: 28153862 Free article.

8

MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma.

Ferrer I, Quintanal-Villalonga Á, Molina-Pinelo S, Garcia-Heredia JM, Perez M, Suárez R, Ponce-Aix S, Paz-Ares L, Carnero A. Ferrer I, et al. Among authors: perez m. J Exp Clin Cancer Res. 2018 Aug 17;37(1):195. doi: 10.1186/s13046-018-0871-7. J Exp Clin Cancer Res. 2018. PMID: 30119639 Free PMC article.

9

Tumor cell-secreted PLD increases tumor stemness by senescence-mediated communication with microenvironment.

Muñoz-Galván S, Lucena-Cacace A, Perez M, Otero-Albiol D, Gomez-Cambronero J, Carnero A. Muñoz-Galván S, et al. Among authors: perez m. Oncogene. 2019 Feb;38(8):1309-1323. doi: 10.1038/s41388-018-0527-2. Epub 2018 Oct 10. Oncogene. 2019. PMID: 30305726

10

Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness.

Muñoz-Galván S, Felipe-Abrio B, Verdugo-Sivianes EM, Perez M, Jiménez-García MP, Suarez-Martinez E, Estevez-Garcia P, Carnero A. Muñoz-Galván S, et al. Among authors: perez m. Mol Cancer. 2020 Jan 11;19(1):7. doi: 10.1186/s12943-020-1130-z. Mol Cancer. 2020. PMID: 31926547 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

5,388 results

Search Page